# Psoriasis risk allele function in activated Th1/17 cells with “memory” to antigen exposure

**Authors:** Bayazit Yunusbayev, Sergei Ryakhovsky, Radick Altinbaev, Anastasia Kislova, Kseniya Danilko, Liudmila Kraeva, Milyausha Yunusbaeva

PMC · DOI: 10.1371/journal.pone.0344675 · 2026-03-11

## TL;DR

This study identifies a genetic variant linked to psoriasis that affects immune cell activation in response to antigens and microbial exposure.

## Contribution

The paper discovers a causal variant, rs4672505, that reduces B3GNT2 expression in memory Th1/Th17 cells, linking it to psoriasis risk through altered T cell activation.

## Key findings

- The eQTL rs4672505 reduces B3GNT2 expression in antigen-experienced Th1/Th17 cells.
- B3GNT2 deficiency in mice leads to increased T cell activation due to altered CD28 glycosylation.
- The risk allele A is associated with heightened immune responses to antigens and microbial products.

## Abstract

Most causal variants for complex diseases are expected to affect gene regulation in a cell- and context-specific manner. Hence, identification of such dynamically functioning variants requires functional readouts in disease-relevant tissues and context. In this study, we prioritized causal variants for psoriasis by adding functional annotations from disease-relevant cells. We demonstrate that disease-relevant immune cells, unlike most other tissues, possess functional annotations that match candidate causal SNPs. Specifically, we identified an eQTL, rs4672505, that reduces B3GNT2 gene expression only in Th1/Th17 cells with a memory phenotype, i.e., antigen-experienced T helper cells. This eQTL, a likely causal variant, also matched an enhancer chromatin mark exclusive to memory T helper cells and absent in other tissues. A disease-risk allele A at the eQTL correlates with reduced expression of the B3GNT2 glycosyltransferase. B3GNT2 deficiency in murine models reduces the glycosylation of the CD28 co-receptor involved in the CD28/B7 co-stimulation pathway and results in increased T cell activation upon antigen stimulation. We hypothesize that the risk allele A in patients increases the activation of memory Th1/Th17 cells upon re-exposure to antigens, which constitutes “signal 1”. Increased reactivity to antigens depends on “signal 2” via CD28/B7 co-stimulation from antigen-presenting cells that need to encounter microbial products. Hence, this genetic risk mechanism lies at the nexus of the response to specific antigens and microbial exposure, for instance, infection or vaccination, both of which are known to exacerbate psoriasis.

## Linked entities

- **Genes:** B3GNT2 (UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2) [NCBI Gene 10678]
- **Proteins:** CD28 (CD28 molecule)
- **Diseases:** psoriasis (MONDO:0005083)

## Full-text entities

- **Genes:** NCAM1 (neural cell adhesion molecule 1) [NCBI Gene 4684] {aka CD56, MSK39, NCAM}, NPY4R (neuropeptide Y receptor Y4) [NCBI Gene 5540] {aka NPY4-R, PP1, PPYR1, Y4}, PTPRC (protein tyrosine phosphatase receptor type C) [NCBI Gene 5788] {aka B220, CD45, CD45R, GP180, IMD105, L-CA}, TRBV20OR9-2 (T cell receptor beta variable 20/OR9-2 (non-functional)) [NCBI Gene 6962] {aka CDR3, TCRBV20S2, TCRBV2O, TCRBV2S2O}, TNFAIP3 (TNF alpha induced protein 3) [NCBI Gene 7128] {aka A20, AIFBL1, AISBL, OTUD7C, TNFA1P2}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, CD28 (CD28 molecule) [NCBI Gene 940] {aka IMD123, Tp44}, RUNX3 (RUNX family transcription factor 3) [NCBI Gene 864] {aka AML2, CBFA3, PEBP2aC}, CCR4 (C-C motif chemokine receptor 4) [NCBI Gene 1233] {aka CC-CKR-4, CD194, CKR4, CMKBR4, ChemR13, HGCN:14099}, B3GNT2 (UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2) [NCBI Gene 10678] {aka 3-Gn-T1, 3-Gn-T2, B3GN-T2, B3GNT, B3GNT-2, B3GNT1}, IL7R (interleukin 7 receptor) [NCBI Gene 3575] {aka CD127, CDW127, IL-7R-alpha, IL-7Ralpha, IL7RA, IL7Ralpha}, CCR6 (C-C motif chemokine receptor 6) [NCBI Gene 1235] {aka BN-1, C-C CKR-6, CC-CKR-6, CCR-6, CD196, CKR-L3}, CCR3 (C-C motif chemokine receptor 3) [NCBI Gene 1232] {aka C C CKR3, CC-CKR-3, CD193, CKR 3, CKR3, CMKBR3}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, COMMD1 (copper metabolism domain containing 1) [NCBI Gene 150684] {aka C2orf5, MURR1}
- **Diseases:** inflammatory diseases (MESH:D007249), Psoriasis (MESH:D011565), psoriatic arthritis (MESH:D015535), autoimmune diseases (MESH:D001327), Ankylosing spondylitis (MESH:D013167), immune-mediated diseases (MESH:C567355), infection (MESH:D007239)
- **Chemicals:** polylactosamine (MESH:C066929)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** rs10865331, rs11249215, rs13024541, rs1810563, rs582757, rs7536201, rs8016947, rs2103876, rs4672505, rs139691717

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12978443/full.md

---
Source: https://tomesphere.com/paper/PMC12978443